NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NEXEL Co., Ltd.

NEXEL Co., Ltd.

Private
SeoulHealthcare & Life Scienceshttps://nexel.co.kr/

Last Round

Private Equity

Apr 28, 2023

Est. Valuation

$78.47M

Total Funding Raised

$41.38M

Company Overview

NEXEL Co., Ltd. is a biotechnology company that provides drug discovery pipelines and develops high-quality induced pluripotent stem cell (iPSC)-derived cell products.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

iPSC-derived cellsinduced pluripotent stem cellsiPSCiPSC cardiomyocytesstem cell technologyorganoidsdrug screeningtoxicity testingcardiotoxicity testingdisease modelinganimal testing alternativenew approach methodologiesNAMscardiac safetymini-organspreclinical testingcell therapy CDMOcustom cell productioniPSC reprogramming

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NEXEL Co., Ltd. Comparables

Compare NEXEL Co., Ltd. with similar companies based on industry and business-model similarity.

NEXEL Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Celogics
88%
Axol Bioscience
86%
ReproCELL Incorporated
84%

NEXEL Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityApr 28, 2023
Series B ExtensionApr 16, 2021
Series BAug 1, 2019
Series ADec 1, 2017

Key People

Founding team and executive leadership

Choongseong Han

CEO

Executive Team

NEXEL Co., Ltd. Investors

Notable investors and investment history

NEXEL Co., Ltd. investors
InvestorRounds
KDB Capital CorpSeries B Extension
SL InvestmentSeries B Extension
UTC InvestmentSeries B Extension, Series B, Private Equity
Friend Investment PartnersSeries B Extension
Comes InvestmentSeries B Extension, Series B
BSK InvestmentSeries B Extension
Medici InvestmentSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2026

    Monthly visitors increased 48% MoM.

  • Nov 7, 2025

    Monthly visitors grew 100% MoM, reaching 5.7K.

NEXEL Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NEXEL Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NEXEL Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range22
Year Founded2012
Last FundingApr 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.